Sign inCreate account

Report workspace tools

NCT03224507COMPLETEDanonymous

Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma - MASTER Trial

Sponsor

Source record

University of Alabama at Birmingham

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

KRdD followed by auto-HCT, KRdD only

Indication / condition

AI-normalized

Multiple Myeloma

Intervention

Source record

KRdD followed by auto-HCT, KRdD only

Source & freshness

Source record

NCT ID

NCT03224507

Original source

ClinicalTrials.gov

Source last updated

Nov 24, 2023

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03224507

Title

Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma - MASTER Trial

Sponsor

University of Alabama at Birmingham

Status

COMPLETED

Phase

PHASE2

Condition raw

Multiple Myeloma

Condition normalized

Multiple Myeloma

Modality raw

small molecule

Modality normalized

small molecule

Target raw

KRdD followed by auto-HCT, KRdD only

Target normalized

KRdD followed by auto-HCT, KRdD only

Interventions

KRdD followed by auto-HCT, KRdD only

Public preview

Source record

Multiple myeloma (MM), a plasma cell disorder, is the second most common hematologic malignancy in the U.S. No standard curative therapy has yet been found. A variety of therapeutic measures including high dose melphalan, induction therapy, and continuous therapy have been used but the goal of complete response without relapse has not been achieved. More active treatment regimens and better tools for response assessment are needed.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma - MASTER Trial

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03224507

Status

COMPLETED

Phase

PHASE2

Sponsor

University of Alabama at Birmingham

Executive brief

Investment-Ready Snapshot

Multiple myeloma (MM), a plasma cell disorder, is the second most common hematologic malignancy in the U.S. No standard curative therapy has yet been found. A variety of therapeutic measures including high dose melphalan, induction therapy, and continuous therapy have been used but the goal of complete response without relapse has not been achieved. More active treatment regimens and better tools for response assessment are needed.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedNov 24, 2023
Internal syncJun 09, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03224507

Indication

Multiple Myeloma

Modality

small molecule

Target

KRdD followed by auto-HCT, KRdD only

Intervention

KRdD followed by auto-HCT, KRdD only

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.